CB Stock Trades at 1.62x Book Value: Is the Valuation Worth It?

Chubb (CB) is trading at 1.62x trailing price-to-book vs. 1.43x for the industry, supported by strong profitability with ROE of 14.5% (vs. 7.5% industry). The Zacks consensus calls for 2026 EPS growth of 10.3% and revenue growth of 7.3% to $64.34B, alongside 13 upward EPS revisions over the past 60 days. Q2 2026 P&C underwriting income rose 18.8% to $1.94B and the combined ratio improved to 83.8% from 85.6%, while pretax catastrophe losses were $475M; shares have gained 21.3% over the past year.

Analysis

CB’s premium multiple is really a bet on compounding, not just next quarter’s earnings. At this valuation, the stock only stays justified if book value growth and ROE remain materially above peers; if either slips, the de-rating can happen fast because insurers trade on a hybrid of earnings and bond-proxy duration. That makes CB a better quality compounder than a cheap value name, but also means upside from here is probably more about sustaining the franchise than expanding the multiple.

The second-order winner is the disciplined end of the P&C market: if CB keeps walking away from underpriced commercial risk, weaker carriers may be forced to chase volume and accept worse economics. That can help CB and TRV maintain underwriting quality near term, but over 6-18 months it can also create a softer industry pricing backdrop that caps premium growth for everyone. Investment income is the swing factor investors may be underweighting; a faster easing cycle or wider credit spreads would slow the earnings tailwind and reduce the justification for premium book multiples.

The contrarian risk is that consensus is extrapolating recent estimate revisions too far. In this business, one or two quarters of benign cats and strong pricing can mask a turn in rate momentum, and the market often re-rates insurers before the earnings inflection shows up. My base case is that CB remains a hold-to-slight-accumulate on weakness name rather than a chase, with relative value better than absolute upside.

Key Decisions for Investors

• Do not chase CB at current levels; wait for a pullback toward ~1.5x P/B or a sector-wide selloff to add. Falsify the setup if ROE falls below ~13% or tangible book growth drops under 10% for two consecutive quarters.
• Pair trade: long CB / short PGR over the next 3-6 months as a quality-versus-cycle expression. CB has more durable underwriting economics and capital return, while PGR needs continued loss-cost normalization to justify its relative trajectory.
• Use TRV as the cheaper quality proxy if you want P&C exposure without paying CB’s full premium. Reassess the spread if CB’s valuation premium widens further without another leg of estimate revision upgrades.
• Set a watch alert for a 50-75 bp decline in the 10Y Treasury or a meaningful narrowing in credit spreads; that would likely slow CB’s investment-income tailwind and weaken the multiple-support thesis.